Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;48(2):381-399.
doi: 10.1007/s12639-024-01677-z. Epub 2024 May 14.

The efficacy of cercarial antigen loaded on nanoparticles as a potential vaccine candidate in Schistosoma mansoni-infected mice

Affiliations

The efficacy of cercarial antigen loaded on nanoparticles as a potential vaccine candidate in Schistosoma mansoni-infected mice

Dina A S Elguindy et al. J Parasit Dis. 2024 Jun.

Abstract

Schistosomiasis is one of the most common causes of morbidity and mortality from parasitic diseases. Mass treatment has proven to be insufficient because of repeated infection after treatment and the appearance of strains resistant to drug therapy. Hence, immunization is a new approach to control the disease and limit the pathological consequences of schistosomiasis. To evaluate the prophylactic effect of Cercarial antigen (CAP) loaded on chitosan nanoparticles (CSNPs) as a potential vaccine against Schistosoma mansoni-infected mice. 130 mice divided into 2 groups were used: Group I: Control groups (50 mice) subdivided into subgroup Ia (10 mice): Non-infected mice (normal control), subgroup Ib (20 mice): Schistosoma infected mice (infected control) and subgroup Ic (20 mice): Non-infected mice receiving NPs only. Group II: Vaccinated group (80 mice) subdivided equally into subgroup IIa (CAP): Received cercarial antigen and subgroup IIb (CAP + CSNP): Received cercarial antigen loaded on chitosan NPs then both vaccinated groups were infected with S. mansoni 3 weeks following the initial vaccination dose. CAP + CSNP and CAP groups showed significant reduction in adult worms count, hepatic egg count, hepatic granulomas number and size in comparison to the infected control group. Elevation of serum IgG and IgM levels, CD4+ and CD8+ T cell frequencies, IL-4, IL-10 and INF-γ levels was more significant in CAP + CSNP group than CAP group. CAP + CSNP is a promising new preparation of Schistosomal antigens that gave better results than immunization with CAP alone. CSNPs enhanced the immune and protective effect of CAP as validated by parasitological, histopathological and immunohistochemical studies.

Keywords: CAP; Chitosan nanoparticles; Flow cytometry; Immunization; Schistosomiasis mansoni.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
A photomicrograph of liver sections of mice (H&E × 200). A Normal control group (GIa) B Chitosan group (GIc) show normal liver architecture. C Infected control group at 6 weeks P.I.: multiple large schistosomal granulomas around viable ova. D Infected control group at 8 weeks P.I.: multiple granulomas mainly fibrocellular and fibrous surrounding schistosomal ova. E Infected control group at 10 weeks P.I.: multiple schistosomal granulomas mainly fibrocellular and fibrous coalescent with each other around multiple ova. F Infected control group at 12 weeks P.I.: multiple granulomas mainly fibrous coalescent with each other surrounding schistosomal ova
Fig. 2
Fig. 2
A photomicrograph of liver sections of mice of the CAP vaccinated group (GIIa) at different durations (H&E × 200): A 6 weeks P.I.: a granuloma surrounding a schistosome ovum B 8 weeks P.I.: fibrocellular granulomas surrounding schistosomal eggs. C 10 weeks P.I.: a small fibrocellular schistosomal granuloma around multiple ova. D 12 weeks P.I.: a reduction in the size of the cellular schistosomal granuloma
Fig. 3
Fig. 3
A photomicrograph of liver sections of mice of the CAP + CSNP vaccinated group (GIIb) at different durations (H&E × 200): A 6 weeks P.I.: a small granuloma surrounding a schistosomal ovum. B 8 weeks P.I.: a very small fibrocellular granuloma surrounding a schistosomal ovum. C 10 weeks P.I.: a small fibrocellular schistosomal granuloma. D 12 weeks P.I.: a marked reduction in the size of the cellular schistosomal granulomas
Fig. 4
Fig. 4
A photomicrograph of liver sections obtained from Schistosoma mansoni-infected mice (GIb) (Masson trichrome stain × 200): A 6 weeks P.I.: the granuloma was many cellular. B 8 weeks P.I. and C 10 weeks P.I.; the granuloma was fibrocellular. D 12 weeks P.I.: the granulomas were mainly fibrous with marked increase in the fibrous content
Fig. 5
Fig. 5
A photomicrograph of liver sections obtained from mice of CAP group (GIIa) at different durations (Masson trichrome stain × 200): A 6 weeks P.I.: the Schistosome granuloma was mainly cellular. B 8 weeks P.I. and C 10 weeks P.I.: a reduction in the fibrous content of the schistosome granulomas. D 12 weeks P.I.: more reduction in the fibrous content of the schistosome granulomas
Fig. 6
Fig. 6
A photomicrograph of liver sections obtained from mice of CAP + CSNP group (GIIb) at different duartions (Masson trichrome stain × 200): A 6 weeks P.I.: the granuloma was mainly cellular. B 8 weeks P.I. and C 10 weeks P.I.: a reduction in the fibrous content of the granulomas. D 12 weeks P.I.: marked reduction in the fibrous content of the granulomas
Fig. 7
Fig. 7
The relation between IgM and IgG serum levels (mg/ml) in the studied groups at different durations P.I
Fig. 8
Fig. 8
The relation between CD4+ T and CD8+ T cells levels in the studied groups at different durations P.I
Fig. 9
Fig. 9
The relation between IL-4, IL-10 and IFN-γ serum levels (pg/ml) in the studied groups at different durations P.I

References

    1. Abdel-Hakeem SS, Abdel-Samiee MA, Abed GH. An insight into the potential parasitological effect of Schistosoma mansoni antigens in infected mice: prophylactic role of cercarial antigen. Microsc Microanal. 2020;26(4):708–716. doi: 10.1017/S1431927620001695. - DOI - PubMed
    1. Ahmad G, Zhang W, Torben W, Ahrorov A, Damian RT, Wolf RF, et al. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J Infect Dis. 2011;204:1437–1449. doi: 10.1093/infdis/jir545. - DOI - PMC - PubMed
    1. Ahmad G, Zhang W, Torben W, Haskins C, Diggs S, Noor Z, et al. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res. 2009;105:1767–1777. doi: 10.1007/s00436-009-1646-z. - DOI - PMC - PubMed
    1. Alves CC, Araujo N, Bernardes WPOS, Mendes MM, Oliveira SC, Fonseca CT. A strong humoral immune response induced by a vaccine formulation containing rSm29 adsorbed to Alum is associated with protection against Schistosoma mansoni reinfection in mice. Front Immunol. 2018;9:1–12. doi: 10.3389/fimmu.2018.02488. - DOI - PMC - PubMed
    1. Aly NSM, Kim HS, Eraky MA, Kholy AAE, Ali BT, Miyoshi SI, et al. Evaluation of schistosomula lung antigen preparation and soluble egg antigen vaccines on experimental schistosomiasis mansoni. Parasites Hosts Dis. 2023;61(3):251–262. doi: 10.3347/PHD.22154. - DOI - PMC - PubMed

LinkOut - more resources